196 related articles for article (PubMed ID: 30967494)
1. Epstein-Barr virus infection is associated with clinical characteristics and poor prognosis of multiple myeloma.
Xia B; Wang X; Yang R; Mengzhen L; Yang K; Ren L; Li S; Wang S; Zhang Y
Biosci Rep; 2019 Oct; 39(10):. PubMed ID: 30967494
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival.
Visco C; Falisi E; Young KH; Pascarella M; Perbellini O; Carli G; Novella E; Rossi D; Giaretta I; Cavallini C; Scupoli MT; De Rossi A; D'Amore ES; Rassu M; Gaidano G; Pizzolo G; Ambrosetti A; Rodeghiero F
Oncotarget; 2015 Jul; 6(21):18653-63. PubMed ID: 26087198
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma.
Okamoto A; Yanada M; Miura H; Inaguma Y; Tokuda M; Morishima S; Kanie T; Yamamoto Y; Mizuta S; Akatsuka Y; Yoshikawa T; Mizoguchi Y; Nakamura S; Okamoto M; Emi N
Cancer Sci; 2015 Nov; 106(11):1576-81. PubMed ID: 26353084
[TBL] [Abstract][Full Text] [Related]
4. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
[TBL] [Abstract][Full Text] [Related]
5. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.
Maltezas D; Dimopoulos MA; Katodritou I; Repousis P; Pouli A; Terpos E; Panayiotidis P; Delimpasi S; Michalis E; Anargyrou K; Gavriatopoulou M; Stefanoudaki A; Tzenou T; Koulieris E; Sachanas S; Dimou M; Vassilakopoulos TP; Angelopoulou MK; Pangalis GA; Kyrtsonis MC
Hematol Oncol; 2013 Jun; 31(2):96-102. PubMed ID: 22961993
[TBL] [Abstract][Full Text] [Related]
6. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
[TBL] [Abstract][Full Text] [Related]
7. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
9. Semiquantitative PCR analysis of Epstein-Barr virus DNA in clinical samples of patients with EBV-associated diseases.
Meerbach A; Gruhn B; Egerer R; Reischl U; Zintl F; Wutzler P
J Med Virol; 2001 Oct; 65(2):348-57. PubMed ID: 11536243
[TBL] [Abstract][Full Text] [Related]
10. Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma.
Haverkos BM; Gru AA; Geyer SM; Bingman AK; Hemminger JA; Mishra A; Wong HK; Pancholi P; Freud AG; Caligiuri MA; Baiocchi RA; Porcu P
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl(Suppl):S181-S190.e4. PubMed ID: 27521316
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment whole blood Epstein-Barr virus DNA predicts prognosis in Hodgkin lymphoma.
Qin JQ; Yin H; Wu JZ; Chen RZ; Xia Y; Wang L; Zhu HY; Fan L; Li JY; Liang JH; Xu W
Leuk Res; 2021 Aug; 107():106607. PubMed ID: 33957372
[TBL] [Abstract][Full Text] [Related]
12. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
Ruf S; Behnke-Hall K; Gruhn B; Bauer J; Horn M; Beck J; Reiter A; Wagner HJ
J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
[TBL] [Abstract][Full Text] [Related]
13. [The prognostic significance of plasma Epstein-Barr virus DNA in patients with diffuse large B cell lymphoma].
An N; Xie YP; Xu Y; Shi PF; Qian SX
Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):839-841. PubMed ID: 29136714
[TBL] [Abstract][Full Text] [Related]
14. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
15. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
[TBL] [Abstract][Full Text] [Related]
16. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
[TBL] [Abstract][Full Text] [Related]
17. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
19. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction.
Wagner HJ; Wessel M; Jabs W; Smets F; Fischer L; Offner G; Bucsky P
Transplantation; 2001 Sep; 72(6):1012-9. PubMed ID: 11579293
[TBL] [Abstract][Full Text] [Related]
20. Host factors associated with the kinetics of Epstein-Barr virus DNA load in patients with primary Epstein-Barr virus infection.
Nakai H; Kawamura Y; Sugata K; Sugiyama H; Enomoto Y; Asano Y; Ihira M; Ohashi M; Kato T; Yoshikawa T
Microbiol Immunol; 2012 Feb; 56(2):93-8. PubMed ID: 22150751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
